Results 11 to 20 of about 1,603 (142)
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
Haematologica, 2010 Background Selective inhibition of the BCR-ABL tyrosine kinase by RNA interference has been demonstrated in leukemic cells. We, therefore, evaluated specific BCR-ABL small interfering RNA silencing in BCR-ABL-positive cell lines, including those ...
Michael Koldehoff +3 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation tyrosine kinase inhibitor (TKIs). The T315I mutant form of BCR-ABL is the most
Congying Gao +6 more
doaj +1 more source
Allosteric inhibition of BCR-ABL [PDF]
Cell Cycle, 2010 Impaired regulation of kinase activity can lead to a variety of diseases, including cancer. Inhibition of kinase activity has, therefore, been considered an attractive anti-cancer therapeutic strategy. The success of targeted therapy with kinase inhibitors has been well documented with BCR-ABL, where imatinib specifically inhibits kinase activity with ...
A Quamrul, Hassan +2 more
openaire +2 more sources
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. [PDF]
PLoS ONE, 2013 BACKGROUND: BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Recent studies indicate the presence of pre-existing BCR-ABL mutations in a higher percentage of CML patients ...
Zafar Iqbal +19 more
doaj +1 more source
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed Myeloid Cells [PDF]
Journal of Biological Chemistry, 1997 The Philadelphia chromosome, detected in virtually all cases of chronic myelogenous leukemia (CML), is formed by a reciprocal translocation between chromosomes 9 and 22 that fuses BCR-encoded sequences upstream of exon 2 of c-ABL. The BCR-ABL fusion creates a gene whose protein product, p210BCR-ABL, has been implicated as the cause of the disease ...
A, Bhat +5 more
openaire +2 more sources
Cell Reports, 2013 Chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias are characterized by the t(9;22) chromosome, which encodes the BCR/ABL oncogene. Multiple mouse models of CML express BCR/ABL at high levels from non-Bcr promoters, resulting in the ...
Samantha B. Foley +6 more
doaj +1 more source
Cell Communication and Signaling, 2021 Background The fusion oncoprotein Bcr-Abl is mostly located in the cytoplasm, which causes chronic myeloid leukemia (CML). After moving into the nucleus, the fusion protein can induce apoptosis of CML cells.
Yuhang Peng +5 more
doaj +1 more source
Scientific Reports, 2022 In this study, we examined the antileukemic effects of pterostilbene, a natural methylated polyphenol analog of resveratrol that is predominantly found in berries and nuts, using various human and murine leukemic cells, as well as bone marrow samples ...
Shohei Kawakami +11 more
doaj +1 more source
Suppression of autophagy by BCR ABL
Frontiers in Bioscience, 2012 Imatinib and second generation BCR/ABL tyrosine kinase inhibitors (TKIs) serve now as standard therapies for patients with chronic myelogenous leukemia (CML); however, CML stem cells are intrinsically insensitive to the cell death-inducing effects of TKIs, allowing the persistence of a "reservoir" of BCR/ABL-expressing CML-initiating cells potentially ...
CALABRETTA, Bruno, SALOMONI, Paolo
openaire +4 more sources
Jurnal Penyakit Dalam Indonesia, 2018 Introduction. Patients with chronic phase Chronic Myeloid Leukemia (CML) at Hematology-Medical Oncology Clinic Department of Internal Medicine dr. Cipto Mangunkusumo National Hospital who haveperformed cytogenetic and RTPCR BCR-ABL examination showed: Ph
Wulyo Rajabto +3 more
doaj +1 more source